Miller K, Li B, Pierce-Hoffman H, Patel S, Lei X, Rajesh A
Nat Commun. 2025; 16(1):2229.
PMID: 40044657
PMC: 11882782.
DOI: 10.1038/s41467-025-57229-3.
Ribeiro J, Etlioglu E, Buset J, Janssen A, Puype H, Berden L
iScience. 2025; 28(2):111853.
PMID: 39967878
PMC: 11834077.
DOI: 10.1016/j.isci.2025.111853.
Lee W, Cho J, Yoo S, Park E
Nutr Res Pract. 2025; 19(1):30-40.
PMID: 39959753
PMC: 11821775.
DOI: 10.4162/nrp.2025.19.1.30.
Xie X, Liu J
Histochem Cell Biol. 2024; 163(1):20.
PMID: 39715938
DOI: 10.1007/s00418-024-02352-3.
Das S, Karmakar S, Venkatachalapathy H, Jha R, Batchelor E, Levens D
Mol Cell. 2024; 84(21):4059-4078.e10.
PMID: 39481385
PMC: 11560571.
DOI: 10.1016/j.molcel.2024.10.006.
Crosstalk between BER and NHEJ in XRCC4-Deficient Cells Depending on hTERT Overexpression.
Sergeeva S, Loshchenova P, Oshchepkov D, Orishchenko K
Int J Mol Sci. 2024; 25(19).
PMID: 39408734
PMC: 11476898.
DOI: 10.3390/ijms251910405.
Suppression of neuronal CDK9/p53/VDAC signaling provides bioenergetic support and improves post-stroke neuropsychiatric outcomes.
Xia J, Zhang T, Sun Y, Huang Z, Shi D, Qin D
Cell Mol Life Sci. 2024; 81(1):384.
PMID: 39235466
PMC: 11377386.
DOI: 10.1007/s00018-024-05428-4.
Immunogenomic profiles and therapeutic options of the pan-programmed cell death-related lncRNA signature for patients with bladder cancer.
Yang J, Zhang L, Zhu B, Wu H, Peng M
Sci Rep. 2024; 14(1):18500.
PMID: 39122807
PMC: 11316077.
DOI: 10.1038/s41598-024-68859-w.
and Its Potential Influence on Key Oncogenic Pathways.
Hamwi M, Elsayed E, Dabash H, Abuawad A, Aweer N, Al Zeir F
Cells. 2024; 13(13.
PMID: 38994962
PMC: 11240681.
DOI: 10.3390/cells13131109.
From Cell Populations to Molecular Complexes: Multiplexed Multimodal Microscopy to Explore p53-53BP1 Molecular Interaction.
Pelicci S, Furia L, Pelicci P, Faretta M
Int J Mol Sci. 2024; 25(9).
PMID: 38731890
PMC: 11083188.
DOI: 10.3390/ijms25094672.
The AsiDNA™ decoy mimicking DSBs protects the normal tissue from radiation toxicity through a DNA-PK/p53/p21-dependent G1/S arrest.
Sesink A, Becerra M, Ruan J, Leboucher S, Dubail M, Heinrich S
NAR Cancer. 2024; 6(1):zcae011.
PMID: 38476631
PMC: 10928987.
DOI: 10.1093/narcan/zcae011.
Jun Dimerization Protein 2 (JDP2) Increases p53 Transactivation by Decreasing MDM2.
Price K, Yang W, Cardoso L, Wang C, Yang R, Yang W
Cancers (Basel). 2024; 16(5).
PMID: 38473360
PMC: 10930919.
DOI: 10.3390/cancers16051000.
Aberrant ATM signaling and homology-directed DNA repair as a vulnerability of p53-mutant GBM to AZD1390-mediated radiosensitization.
Chen J, Laverty D, Talele S, Bale A, Carlson B, Porath K
Sci Transl Med. 2024; 16(734):eadj5962.
PMID: 38354228
PMC: 11064970.
DOI: 10.1126/scitranslmed.adj5962.
A CANCER PERSISTENT DNA REPAIR CIRCUIT DRIVEN BY MDM2, MDM4 (MDMX), AND MUTANT P53 FOR RECRUITMENT OF MDC1 AND 53BP1 TO CHROMATIN.
Ellison V, Polotskaia A, Xiao G, Leybengrub P, Qiu W, Lee R
bioRxiv. 2024; .
PMID: 38328189
PMC: 10849484.
DOI: 10.1101/2024.01.20.576487.
Key Proteins of Replication Stress Response and Cell Cycle Control as Cancer Therapy Targets.
Khamidullina A, Abramenko Y, Bruter A, Tatarskiy V
Int J Mol Sci. 2024; 25(2).
PMID: 38279263
PMC: 10816012.
DOI: 10.3390/ijms25021263.
Proteomic analysis reveals LRPAP1 as a key player in the micropapillary pattern metastasis of lung adenocarcinoma.
Yan H, Lin S, Xu S, Gao Y, Zhou B, Zhou R
Heliyon. 2024; 10(1):e23913.
PMID: 38226250
PMC: 10788494.
DOI: 10.1016/j.heliyon.2023.e23913.
Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.
Madorsky Rowdo F, Xiao G, Khramtsova G, Nguyen J, Martini R, Stonaker B
Cancer Lett. 2024; 584:216608.
PMID: 38199587
PMC: 10922546.
DOI: 10.1016/j.canlet.2024.216608.
CDKN1A/p21 in Breast Cancer: Part of the Problem, or Part of the Solution?.
Manousakis E, Miralles C, Esquerda M, Wright R
Int J Mol Sci. 2023; 24(24).
PMID: 38139316
PMC: 10743848.
DOI: 10.3390/ijms242417488.
Environmental pollutants and phosphoinositide signaling in autoimmunity.
Ren C, Carrillo N, Cryns V, Anderson R, Chen M
J Hazard Mater. 2023; 465:133080.
PMID: 38091799
PMC: 10923067.
DOI: 10.1016/j.jhazmat.2023.133080.
Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.
Madorsky Rowdo F, Xiao G, Khramtsova G, Nguyen J, Olopade O, Martini R
bioRxiv. 2023; .
PMID: 38076873
PMC: 10705575.
DOI: 10.1101/2023.06.22.544406.